SK Bioscience Co.,Ltd
Financials
Valuation Metrics
SK Bioscience Co.,Ltd's Market Cap is ₩2.7T. At end of 2025 it was ₩3.8T. Ranked #155 of 2,436 in KR market (top 6%), #131 of 787 on KOSPI (top 17%), #16 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.72T KRW | KR#155/2,436 Sec#16/234 |
| Revenue | 665.42B KRW | KR#510/2,436 Sec#21/234 |
| Net Income | -88.27B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 2.99T KRW | KR#232/2,436 Sec#7/234 |
| Net Assets | 2.02T KRW | KR#178/2,436 Sec#5/234 |
| Employees | 1,021 | KR#251/2,436 Sec#18/234 |
| Value | ||
| P/B | 1.34x | KR#1,718/2,436 Sec#122/234 |
| P/S | 4.09x | KR#2,098/2,436 Sec#136/234 |
| FCF Yield | -2.96% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -4.36% | KR#1,728/2,436 Sec#127/234 |
| ROA | -2.95% | KR#1,756/2,436 Sec#128/234 |
| Op. Margin | -22.98% | KR#2,147/2,436 Sec#146/234 |
| Revenue Growth | 9.09% | KR#960/2,436 Sec#85/234 |
| Financial Health | ||
| Debt Ratio | 147.85% | KR#1,160/2,436 Sec#132/234 |
| Total Debt | 1.07T KRW | KR#190/2,436 Sec#4/234 |
| FCF | -80.58B KRW | KR#2,126/2,436 Sec#211/234 |
| Cash | 86.72B KRW | KR#508/2,436 Sec#26/234 |
| Current Ratio | 4.04x | KR#409/2,436 Sec#71/234 |
| Performance | ||
| 1Y Return | -22.22% | KR#1,333/2,436 Sec#110/234 |
| 1M Return | -8.09% | KR#1,639/2,436 Sec#165/234 |
| From 52W High | -43.47% | KR#915/2,436 Sec#67/234 |
| 1Y MDD | -45.92% | KR#745/2,436 Sec#61/234 |
| Trading | ||
| Volume | 80,463 shares | KR#1,063/2,436 Sec#101/234 |
| Foreign Own. | 5.89% | KR#716/2,436 Sec#70/234 |
| Per Share | ||
| EPS | -1,062 KRW | KR—/2,436 Sec—/234 |
| BPS | 22,571 KRW | KR#463/2,436 Sec#31/234 |
Company Info
SK Bioscience was established in 2018 through a spin-off of SK Chemical's vaccine business division, officially entering the global market in 2024 with the acquisition of a German CDMO specialized company. Its core businesses are vaccine/biopharmaceutical research and development, production, sales, and CDMO, with revenue composed of 18.4% proprietary vaccines, 7.6% product sales, and 74.0% CDMO. The company develops disease prevention and treatment pharmaceuticals using diverse vaccine production technologies. SK Bioscience is executing a strategy to grow into a Global Top 10 Vaccine Company and is headquartered in Seongnam-si, Gyeonggi-do.